Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose escalation trial of cloretazine (VNP40101M) and hematopoietic cell transplantation for patients with selected, poor-prognosis hematologic malignancies.

Trial Profile

Dose escalation trial of cloretazine (VNP40101M) and hematopoietic cell transplantation for patients with selected, poor-prognosis hematologic malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2015

At a glance

  • Drugs Fludarabine; Laromustine
  • Indications Graft-versus-host disease; Haematological malignancies; Hodgkin's disease; Leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Dec 2010 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 14 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Oct 2010 Planned end date changed from 1 Aug 2009 to 1 Aug 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top